On October 23, CSPC PHARMA fell 3.11% in Regular Trading, trading at HK$8.125, with turnover of HK$113 million.

The key disclosed catalyst was an event-driven update: the company said batoclimab injection had received a drug registration certificate in China for use with conventional therapy in adult patients with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis.

The approval is notable because the product was described as the first anti-FcRn therapy to complete full clinical development for gMG in China. The asset was introduced from Harbour BioMed by a CSPC subsidiary, adding to a recent stream of pipeline updates including oncology clinical approvals and trial disclosures, but the positive regulatory news did not prevent the stock from moving lower during the session.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)